file1
,
file2
, etc. all in the same folder or directory;
first, locate one of the files with the [Browse...] button. Then alter the
file path in the box above to include '*' character (eg. file*
).
Wildcard '?' to blanket only one character works too.Historiographs |
Grand Totals: LCS 17722, GCS 106366, CR 136943 Collection span: 1963 - 2012 | |
Word(i) List (4568) Word count: 24159, All words count: 34321 |
# | Word | Recs | TLCS | TGCS |
---|---|---|---|---|
201 | PHARMACOKINETICS | 20 | 114 | 1092 |
202 | STRATEGIES | 20 | 29 | 368 |
203 | VITRO | 20 | 63 | 571 |
204 | HISTOCOMPATIBILITY | 19 | 92 | 401 |
205 | INFECTION | 19 | 7 | 317 |
206 | RECEIVING | 19 | 119 | 727 |
207 | SERA | 19 | 101 | 466 |
208 | SUCCESSFUL | 19 | 110 | 467 |
209 | SYSTEMIC | 19 | 235 | 657 |
210 | VASCULARIZED | 19 | 55 | 208 |
211 | AUTOIMMUNE | 18 | 20 | 408 |
212 | CYTOKINE | 18 | 79 | 532 |
213 | HEPATITIS | 18 | 27 | 589 |
214 | HISTORY | 18 | 17 | 339 |
215 | IMMUNOLOGY | 18 | 29 | 186 |
216 | IMPACT | 18 | 52 | 612 |
217 | INJECTION | 18 | 21 | 125 |
218 | INVITRO | 18 | 37 | 419 |
219 | LEVELS | 18 | 77 | 517 |
220 | MONOTHERAPY | 18 | 75 | 491 |
221 | PATIENT | 18 | 28 | 215 |
222 | REGENERATION | 18 | 102 | 894 |
223 | SPONTANEOUS | 18 | 115 | 337 |
224 | ACTIVATION | 17 | 57 | 615 |
225 | AGENT | 17 | 48 | 652 |
226 | ANTI-LYMPHOCYTE | 17 | 68 | 445 |
227 | ANTIBODIES | 17 | 23 | 142 |
228 | ANTILYMPHOCYTIC | 17 | 68 | 368 |
229 | COMBINATION | 17 | 48 | 582 |
230 | FUNCTIONAL | 17 | 136 | 590 |
# | Word | Recs | TLCS | TGCS |
231 | KIDNEYS | 17 | 34 | 235 |
232 | LEUKOCYTE | 17 | 80 | 279 |
233 | MULTIPLE | 17 | 112 | 890 |
234 | OBSERVATIONS | 17 | 92 | 700 |
235 | PROLIFERATION | 17 | 47 | 560 |
236 | QUANTITATIVE | 17 | 8 | 220 |
237 | RABBIT | 17 | 44 | 307 |
238 | THYMUS | 17 | 45 | 419 |
239 | ANTIGENS | 16 | 25 | 302 |
240 | ENGRAFTMENT | 16 | 50 | 172 |
241 | IDENTIFICATION | 16 | 59 | 454 |
242 | IMPLICATIONS | 16 | 134 | 472 |
243 | LIVING-RELATED | 16 | 89 | 507 |
244 | MOUSE | 16 | 96 | 452 |
245 | PARTICULAR | 16 | 184 | 523 |
246 | POLYMERASE | 16 | 108 | 238 |
247 | PRETREATMENT | 16 | 110 | 440 |
248 | PROLONGED | 16 | 60 | 242 |
249 | PROTEIN | 16 | 35 | 818 |
250 | RISK | 16 | 25 | 560 |
251 | SYNTHESIS | 16 | 47 | 626 |
252 | USED | 16 | 61 | 337 |
253 | DNA | 15 | 15 | 203 |
254 | IN-VITRO | 15 | 63 | 403 |
255 | INCREASED | 15 | 22 | 251 |
256 | INDUCE | 15 | 94 | 521 |
257 | LYMPHOID | 15 | 111 | 362 |
258 | PORTAL | 15 | 20 | 205 |
259 | POSTTRANSPLANT | 15 | 67 | 495 |
260 | POTENTIAL | 15 | 63 | 584 |
# | Word | Recs | TLCS | TGCS |
261 | PROSPECTS | 15 | 30 | 180 |
262 | REACTIVITY | 15 | 89 | 666 |
263 | REGULATION | 15 | 51 | 402 |
264 | SPLEEN | 15 | 12 | 42 |
265 | ASSESSMENT | 14 | 67 | 319 |
266 | AUGMENTATION | 14 | 257 | 497 |
267 | CASE | 14 | 30 | 205 |
268 | CONVERSION | 14 | 156 | 441 |
269 | DOGS | 14 | 73 | 626 |
270 | FLOW | 14 | 59 | 216 |
271 | HYPERTENSION | 14 | 19 | 553 |
272 | LIMB | 14 | 35 | 104 |
273 | MAJOR | 14 | 46 | 404 |
274 | OVERGROWTH | 14 | 15 | 201 |
275 | PREDNISONE | 14 | 395 | 1132 |
276 | PREPARATION | 14 | 55 | 342 |
277 | PRESENCE | 14 | 188 | 752 |
278 | PRESENT | 14 | 36 | 366 |
279 | REGULATORY | 14 | 32 | 224 |
280 | RENAL-ALLOGRAFTS | 14 | 49 | 310 |
281 | SINGLE | 14 | 77 | 1091 |
282 | STEROID | 14 | 45 | 392 |
283 | SURGICAL | 14 | 12 | 222 |
284 | SYNDROME | 14 | 45 | 357 |
285 | APOPTOSIS | 13 | 85 | 393 |
286 | APPLICATION | 13 | 40 | 327 |
287 | CHARACTERIZATION | 13 | 69 | 411 |
288 | CONSIDERATIONS | 13 | 31 | 291 |
289 | DIFFERENT | 13 | 135 | 312 |
290 | GENE | 13 | 13 | 240 |
# | Word | Recs | TLCS | TGCS |
291 | HEMODIALYSIS | 13 | 10 | 391 |
292 | HOMOGRAFTS | 13 | 339 | 686 |
293 | HUMORAL | 13 | 21 | 198 |
294 | LOW-DOSE | 13 | 60 | 381 |
295 | NORMAL | 13 | 72 | 344 |
296 | ORAL | 13 | 28 | 255 |
297 | ORIGIN | 13 | 27 | 439 |
298 | PROGENITORS | 13 | 346 | 1324 |
299 | PROPERTIES | 13 | 53 | 278 |
300 | REVERSAL | 13 | 344 | 738 |
301 | SPECIAL | 13 | 207 | 754 |
302 | SPECIFIC | 13 | 36 | 301 |
303 | SYSTEM | 13 | 18 | 228 |
304 | TYPE | 13 | 13 | 113 |
305 | VASCULAR | 13 | 22 | 374 |
306 | APPROACH | 12 | 51 | 234 |
307 | CALCINEURIN | 12 | 9 | 341 |
308 | CIRCULATING | 12 | 28 | 596 |
309 | CUTANEOUS | 12 | 38 | 687 |
310 | DIAGNOSIS | 12 | 42 | 291 |
311 | DISORDERS | 12 | 26 | 334 |
312 | PASSENGER | 12 | 120 | 261 |
313 | PERSPECTIVE | 12 | 117 | 252 |
314 | PERSPECTIVES | 12 | 48 | 313 |
315 | PRIMATES | 12 | 44 | 251 |
316 | RECEPTOR | 12 | 12 | 577 |
317 | SINGLE-CENTER | 12 | 55 | 430 |
318 | SPLENECTOMY | 12 | 20 | 218 |
319 | TECHNIQUE | 12 | 28 | 68 |
320 | VIRUS | 12 | 29 | 851 |
# | Word | Recs | TLCS | TGCS |
321 | CHIMERIC | 11 | 66 | 158 |
322 | CONCEPTS | 11 | 28 | 256 |
323 | DEATH | 11 | 39 | 466 |
324 | DISEASES | 11 | 22 | 345 |
325 | EVOLUTION | 11 | 81 | 987 |
326 | GROWTH | 11 | 81 | 288 |
327 | IMMUNOSUPPRESSANTS | 11 | 33 | 317 |
328 | INTRATHYMIC | 11 | 20 | 61 |
329 | INVIVO | 11 | 9 | 230 |
330 | ISCHEMIA | 11 | 20 | 356 |
331 | LATE | 11 | 61 | 319 |
332 | LIGAND | 11 | 91 | 915 |
333 | LYMPHOPROLIFERATIVE | 11 | 16 | 261 |
334 | MAINTENANCE | 11 | 95 | 306 |
335 | MELLITUS | 11 | 12 | 396 |
336 | MOLECULAR | 11 | 9 | 95 |
337 | MONKEYS | 11 | 25 | 164 |
338 | MULTIVISCERAL | 11 | 19 | 133 |
339 | OUTCOMES | 11 | 47 | 383 |
340 | PATTERNS | 11 | 39 | 191 |
341 | PCR | 11 | 49 | 100 |
342 | PERSISTENCE | 11 | 109 | 263 |
343 | POSSIBLE | 11 | 42 | 309 |
344 | PROGRESS | 11 | 34 | 239 |
345 | REACTIONS | 11 | 140 | 385 |
346 | RECURRENT | 11 | 18 | 199 |
347 | REGIMENS | 11 | 14 | 194 |
348 | SEVERE | 11 | 45 | 266 |
349 | SIGNIFICANCE | 11 | 64 | 343 |
350 | SMALL-BOWEL | 11 | 18 | 92 |
# | Word | Recs | TLCS | TGCS |
351 | SURGERY | 11 | 1 | 74 |
352 | TOXICITY | 11 | 37 | 443 |
353 | URINARY | 11 | 23 | 317 |
354 | VENOUS | 11 | 17 | 155 |
355 | XENOGENEIC | 11 | 24 | 601 |
356 | ACQUIRED | 10 | 12 | 57 |
357 | ADVANCES | 10 | 20 | 188 |
358 | ANTI-THYMOCYTE | 10 | 70 | 359 |
359 | APPLICATIONS | 10 | 11 | 122 |
360 | CLINICAL-TRIAL | 10 | 137 | 706 |
361 | COMPARATIVE | 10 | 39 | 380 |
362 | CONCENTRATIONS | 10 | 52 | 257 |
363 | CORRELATES | 10 | 47 | 258 |
364 | DOG | 10 | 88 | 331 |
365 | ERA | 10 | 25 | 331 |
366 | HEPATOCYTES | 10 | 21 | 103 |
367 | HYPORESPONSIVENESS | 10 | 56 | 397 |
368 | IN-VIVO | 10 | 16 | 364 |
369 | INITIAL | 10 | 20 | 312 |
370 | MATCHING | 10 | 112 | 426 |
371 | MULTICENTER | 10 | 55 | 371 |
372 | PAST | 10 | 7 | 220 |
373 | PATHOGENESIS | 10 | 14 | 431 |
374 | PRELIMINARY | 10 | 27 | 245 |
375 | PROBLEMS | 10 | 16 | 179 |
376 | PULMONARY | 10 | 26 | 339 |
377 | REPLACEMENT | 10 | 32 | 450 |
378 | TOLERANT | 10 | 81 | 250 |
379 | TOPICAL | 10 | 15 | 336 |
380 | TUMOR | 10 | 13 | 136 |
# | Word | Recs | TLCS | TGCS |
381 | VALUE | 10 | 4 | 70 |
382 | VIVO | 10 | 41 | 332 |
383 | XENOGRAFTS | 10 | 13 | 92 |
384 | ALG | 9 | 70 | 333 |
385 | APPROACHES | 9 | 4 | 220 |
386 | ATG | 9 | 48 | 159 |
387 | BIOPSIES | 9 | 21 | 269 |
388 | CANCER | 9 | 2 | 204 |
389 | CD8 | 9 | 38 | 444 |
390 | CHAIN | 9 | 49 | 123 |
391 | COMPARING | 9 | 71 | 597 |
392 | CYTOTOXIC | 9 | 139 | 545 |
393 | DIABETES-MELLITUS | 9 | 35 | 392 |
394 | DRAINAGE | 9 | 21 | 131 |
395 | EPISODES | 9 | 63 | 274 |
396 | ESTABLISHED | 9 | 63 | 131 |
397 | FACTOR | 9 | 125 | 476 |
398 | FEATURES | 9 | 23 | 479 |
399 | GLOMERULAR | 9 | 29 | 324 |
400 | HETEROTRANSPLANTATION | 9 | 121 | 569 |